|
AUPO755097A0
(en)
|
1997-06-25 |
1997-07-17 |
University Of Queensland, The |
Receptor agonist and antagonist
|
|
AUPQ339899A0
(en)
|
1999-10-13 |
1999-11-04 |
University Of Queensland, The |
Novel molecules
|
|
ES2353077T3
(es)
|
2000-08-10 |
2011-02-25 |
Mitsubishi Tanabe Pharma Corporation |
Derivados de urea con sustitución en posición 3 y uso medicinal de los mismos.
|
|
CN1474803B
(zh)
|
2000-09-14 |
2012-11-21 |
田边三菱制药株式会社 |
酰胺衍生物及其制备药物的用途
|
|
AUPR833401A0
(en)
*
|
2001-10-17 |
2001-11-08 |
University Of Queensland, The |
G protein-coupled receptor antagonists
|
|
US8524862B2
(en)
|
2002-03-19 |
2013-09-03 |
Cincinnati Children's Hospital Medical Center |
Muteins of C5a anaphylatoxin and methods of inhibiting C5a
|
|
US20040014782A1
(en)
*
|
2002-03-29 |
2004-01-22 |
Krause James E. |
Combination therapy for the treatment of diseases involving inflammatory components
|
|
AUPS160602A0
(en)
*
|
2002-04-08 |
2002-05-16 |
University Of Queensland, The |
Therapeutic method
|
|
AU2002950657A0
(en)
|
2002-08-08 |
2002-09-12 |
Alchemia Limited |
Derivatives of monosaccharides for drug discovery
|
|
AU2002951995A0
(en)
*
|
2002-10-11 |
2002-10-31 |
Alchemia Limited |
Classes of compounds that interact with gpcrs
|
|
AU2003266858B2
(en)
*
|
2002-10-11 |
2006-09-14 |
Vast Bioscience Pty Limited |
Classes of compounds that interact with GPCRs
|
|
AU2002952086A0
(en)
*
|
2002-10-16 |
2002-11-07 |
The University Of Queensland |
Treatment of osteoarthritis
|
|
WO2004035078A1
(en)
*
|
2002-10-16 |
2004-04-29 |
The University Of Queensland |
Treatment of inflammatory bowel disease
|
|
AU2002952129A0
(en)
*
|
2002-10-17 |
2002-10-31 |
The University Of Queensland |
Treatment of hypersensitivity conditions
|
|
AU2003902354A0
(en)
*
|
2003-05-15 |
2003-05-29 |
Harkin, Denis W. |
Treatment of haemorrhagic shock
|
|
AU2003902586A0
(en)
*
|
2003-05-26 |
2003-06-12 |
The University Of Queensland |
Treatment of burns
|
|
WO2005014849A2
(en)
*
|
2003-07-03 |
2005-02-17 |
Euro-Celtique, S.A. |
Genes associated with responses to neuropathic pain
|
|
EP1498422A1
(de)
*
|
2003-07-17 |
2005-01-19 |
Jerini AG |
C5a-Rezeptor-Antagonisten
|
|
CN101036057A
(zh)
*
|
2004-10-04 |
2007-09-12 |
阿尔卡米亚有限公司 |
选择性抑制剂
|
|
JP2008526915A
(ja)
*
|
2005-01-17 |
2008-07-24 |
イエリニ・アクチェンゲゼルシャフト |
Ｃ５ａ受容体アンタゴニスト
|
|
EP1861114B1
(en)
*
|
2005-03-11 |
2011-02-02 |
Potentia Pharmaceuticals, Inc. |
Compositions comprising modulators of g-protein-coupled receptor for treatment of macular degeneration
|
|
EP1739078A1
(de)
|
2005-05-30 |
2007-01-03 |
Jerini AG |
C5a-Rezeptor-Antagonisten
|
|
US20070292421A1
(en)
*
|
2005-07-28 |
2007-12-20 |
Feinberg Bruce B |
Method for treating preeclampsia
|
|
US8168584B2
(en)
|
2005-10-08 |
2012-05-01 |
Potentia Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration by compstatin and analogs thereof
|
|
PL2148691T3
(pl)
|
2007-02-05 |
2015-12-31 |
Apellis Pharmaceuticals Inc |
Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
|
|
US20110092446A1
(en)
*
|
2007-07-20 |
2011-04-21 |
Cedric Francois |
Compositions and methods for treatment of trauma
|
|
EP2278987A4
(en)
*
|
2008-03-28 |
2012-08-22 |
Apellis Ag |
MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM
|
|
JP2011526738A
(ja)
*
|
2008-07-02 |
2011-10-13 |
サンゴバン・パフォーマンス・プラスティックス・シェンヌー |
枠付き装置、封止材およびその製造方法
|
|
BRPI0921237A2
(pt)
|
2008-11-10 |
2015-09-22 |
Alexion Pharma Inc |
métodos e composições para o tratamento de distúrbios associados ao complemento
|
|
EP2525814A4
(en)
*
|
2010-01-22 |
2013-09-11 |
Univ Louisville Res Found |
METHODS OF TREATING OR PREVENTING PERIODONTITIS AND PARODONTIST-RELATED DISEASES
|
|
WO2011137395A1
(en)
|
2010-04-30 |
2011-11-03 |
Rother Russell P |
Anti-c5a antibodies and methods for using the antibodies
|
|
EP2588121A4
(en)
*
|
2010-06-29 |
2013-12-04 |
Univ Nebraska |
C5A ANALOGUE AND USE METHOD THEREFOR
|
|
EP2468295A1
(en)
|
2010-12-21 |
2012-06-27 |
Affiris AG |
Vaccines based on peptides of the complement protein C5a
|
|
BR112013033272A2
(pt)
|
2011-06-22 |
2020-11-10 |
Apellis Pharmaceuticals, Inc. |
composição farmaceutica compreendendo um inibidor do complemento e um agente anti-th17, e usos dos mesmos
|
|
US9289467B2
(en)
|
2011-08-10 |
2016-03-22 |
Case Western Reserve University |
Compositions and methods for treating bone conditions
|
|
WO2014043223A1
(en)
*
|
2012-09-11 |
2014-03-20 |
Hospital For Special Surgery |
Irhom2 inhibition for the treatment of complement mediated disorders
|
|
ES2879430T3
(es)
|
2012-11-15 |
2021-11-22 |
Apellis Pharmaceuticals Inc |
Análogos de compstatina de acción prolongada y composiciones y métodos relacionados
|
|
WO2014152391A1
(en)
|
2013-03-15 |
2014-09-25 |
Apellis Pharmaceuticals, Inc. |
Cell-penetrating compstatin analogs and uses thereof
|
|
AU2014248252A1
(en)
*
|
2013-04-02 |
2015-10-29 |
M. Reza Ghadiri |
Uses of cyclic peptides for treating and preventing atherosclerosis
|
|
EP3290922A1
(en)
|
2013-08-07 |
2018-03-07 |
Alexion Pharmaceuticals, Inc. |
Atypical hemolytic uremic syndrome (ahus) biomarker proteins
|
|
FI3359555T3
(fi)
|
2015-10-07 |
2024-03-20 |
Apellis Pharmaceuticals Inc |
Annostusohjeet
|
|
MA45770A
(fr)
|
2016-07-29 |
2019-06-05 |
Pfizer |
Peptides cycliques en tant qu'antagonistes du récepteur c5
|
|
JP7128182B2
(ja)
|
2016-10-27 |
2022-08-30 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
補体関連障害におけるＣ５ｂ－９沈着に関するアッセイ
|
|
ES2893769T3
(es)
|
2017-04-03 |
2022-02-10 |
Inflarx Gmbh |
Tratamiento de enfermedades inflamatorias con inhibidores de la actividad de C5a
|
|
US10376595B2
(en)
|
2017-04-03 |
2019-08-13 |
Inflarx Gmbh |
Treatment of inflammatory diseases with inhibitors of C5a activity
|
|
JP2020516607A
(ja)
|
2017-04-07 |
2020-06-11 |
アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
投与レジメンならびに関連組成物および方法
|
|
EP3642230A1
(en)
|
2017-06-23 |
2020-04-29 |
InflaRx GmbH |
Treatment of inflammatory diseases with inhibitors of c5a activity
|
|
WO2019118938A1
(en)
|
2017-12-15 |
2019-06-20 |
Apellis Pharmaceuticals, Inc. |
Dosing regimens and related compositions and methods
|
|
WO2021067526A1
(en)
|
2019-10-02 |
2021-04-08 |
Alexion Pharmaceuticals, Inc. |
Complement inhibitors for treating drug-induced complement-mediated response
|
|
EP4126222A1
(en)
|
2020-03-27 |
2023-02-08 |
InflaRx GmbH |
Inhibitors of c5a for the treatment of corona virus infection
|
|
CN115667925A
(zh)
|
2020-05-15 |
2023-01-31 |
阿雷克森制药公司 |
使用细胞外囊泡来检测补体激活的方法以及其用于评估和/或监测补体介导的疾病的治疗的用途
|
|
WO2024238421A1
(en)
|
2023-05-12 |
2024-11-21 |
Alexion Pharmaceuticals, Inc. |
Use of biomarkers for the identification and treatment of complement-mediated disorders
|
|
WO2024238422A1
(en)
|
2023-05-12 |
2024-11-21 |
Alexion Pharmaceuticals, Inc. |
Use of a panel of lectins for detection of complement biomarkers in urine extracellular vesicles
|
|
US12180274B2
(en)
|
2023-05-26 |
2024-12-31 |
Inflarx Gmbh |
Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
|